A phase I study of binimetinib (MEK 162), a MEK inhibitor, plus carboplatin and pemetrexed chemotherapy in non-squamous non-small cell lung cancer
A. S. Fung, D. M. Graham, E. X. Chen, T. L. Stockley, T. Zhang, L. W. Le, H. Albaba, K. M. Pisters, P. A. Bradbury, M. Trinkaus, M. Chan, S. Arif, U. Zurawska, J. Rothenstein, D. Zawisza, S. Effendi, S. Gill, M. Sawczak, J. H. Law, N. B. Leighl
Dive into the research topics of 'A phase I study of binimetinib (MEK 162), a MEK inhibitor, plus carboplatin and pemetrexed chemotherapy in non-squamous non-small cell lung cancer'. Together they form a unique fingerprint.